Funding to Underpin Further Advances in Cancer Therapies

Biotech Grey Wolf Therapeutics, focused on developing therapies for immuno-oncology (IO), has completed a £2.5 million ($3.3 million) Series A2 financing round with existing leading international healthcare investors Andera Partners and Canaan.

The new funding – all from existing investors – will accelerate development of therapies targeting endoplasmic reticulum aminopeptidase 2 (ERAP2), following positive signals of its potential and also be used to continue to drive the lead endoplasmic reticulum aminopeptidase 1 (ERAP1) modulator program. Both approaches are aimed at directly altering tumour cells, illuminating them for attack and destruction by the immune system. The goal is to exploit this increased tumour visibility in monotherapy and to extend the therapeutic benefit of already approved immunotherapies to many more cancers.

"We are delighted to have the continued support of Andera and Canaan." said Peter Joyce, Chief Executive Officer and Co-Founder. "The financing reflects growing potential in both our ERAP1 and ERAP2 approaches. We continue to see momentum, both in our own work and in the broader scientific community. These funds will allow us to further capitalise on this opportunity and expand our leadership position in the discovery and development of both ERAP1 and ERAP2 modulators."

“We have continued to generate data showing that modulation of both ERAP pathways drives change to the cancer-related antigen repertoire," said Tom McCarthy, Executive Chairman and Co-Founder of Grey Wolf Therapeutics. "Data clearly demonstrates that modulation of ERAP2 drives an altogether different change to the antigen repertoire, when compared with ERAP1 modulation, due to ERAP2’s clearly differentiated peptide substrate specificities. With this investment and the prior knowledge base within Grey Wolf we will be able to accelerate the ERAP2 program quickly."